• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在小鼠肝细胞癌变过程中蛋白酶体库的变化。

Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.

机构信息

Koltsov Institute for Developmental Biology, Russian Academy of Sciences.

出版信息

Acta Naturae. 2010 Apr;2(1):102-8.

PMID:22649635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3347545/
Abstract

Multiple forms of proteasomes regulate cellular processes by destroying proteins or forming the peptides involved in those processes. Various pathologies, including carcinogenesis, are related to changes in the functioning of the proteasome forms. In this study, we looked at the changes in the pool of liver proteasomes during nodular regenerative hyperplasia and formation of adenoma and hepatocellular carcinoma in mice treated with Dipin, followed by partial liver resection. The relative content of various proteasome forms was determined using Western blot analysis. The chymotrypsin-like activity of proteasomes was assessed from the hydrolysis of the commercial Suc-LLVY-AMC substrate. It was found that changes in the proteasome pool appeared already during the formation of diffuse nodules, the changes being the increased expression of the X(β5) constitutive subunit and the LMP7(β5i) and LMP2(β1i) immune subunits, accompanied by the increase of the total proteasome pool and the decrease in the chymotrypsin-like activity. These changes were more pronounced in hepatocellular carcinoma. The content of the total proteasome pool and the LMP2(β1i) immune subunit and the chymotrypsin-like activity in adenoma were intermediate compared to those in the samples of liver with diffuse nodules and carcinoma. In addition, the level of the Rpt6 subunit present in the 19S proteasome activator was increased in carcinoma. Our results indicate that nodular regenerative hyperplasia and adenomatosis may be stages preceding carcinogenesis. We also conclude that there is a need to find signalling pathways that change the expression of various proteasome subunits during carcinogenesis. The 19S proteasome activator, which is overexpressed in malignant tumours, can be a promising target for the development of new anticancer drugs.

摘要

多种形式的蛋白酶体通过破坏蛋白质或形成参与这些过程的肽来调节细胞过程。包括癌变在内的各种病理学与蛋白酶体形式功能的变化有关。在这项研究中,我们观察了在用 Dipin 处理的小鼠的结节性再生性增生、腺瘤和肝细胞癌形成过程中,肝脏蛋白酶体库的变化,随后进行了部分肝切除术。使用 Western blot 分析确定了各种蛋白酶体形式的相对含量。通过水解商业 Suc-LLVY-AMC 底物评估蛋白酶体的糜蛋白酶样活性。结果发现,蛋白酶体库的变化早在弥漫性结节形成时就出现了,变化是 X(β5)组成型亚基和 LMP7(β5i)和 LMP2(β1i)免疫亚基的表达增加,伴随着总蛋白酶体库的增加和糜蛋白酶样活性的降低。这些变化在肝细胞癌中更为明显。与弥漫性结节和癌组织样本相比,腺瘤的总蛋白酶体库含量、LMP2(β1i)免疫亚基和糜蛋白酶样活性较低。此外,19S 蛋白酶体激活剂中存在的 Rpt6 亚基水平在癌组织中增加。我们的结果表明,结节性再生性增生和腺瘤可能是癌变前的阶段。我们还得出结论,需要找到在癌变过程中改变各种蛋白酶体亚基表达的信号通路。在恶性肿瘤中过度表达的 19S 蛋白酶体激活剂可以成为开发新抗癌药物的有前途的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a854/3347545/6bb23c831bc7/AN20758251-04-102-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a854/3347545/c7d96820cffa/AN20758251-04-102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a854/3347545/1c92fb68569d/AN20758251-04-102-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a854/3347545/6bb23c831bc7/AN20758251-04-102-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a854/3347545/c7d96820cffa/AN20758251-04-102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a854/3347545/1c92fb68569d/AN20758251-04-102-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a854/3347545/6bb23c831bc7/AN20758251-04-102-g003.jpg

相似文献

1
Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells.在小鼠肝细胞癌变过程中蛋白酶体库的变化。
Acta Naturae. 2010 Apr;2(1):102-8.
2
[Dynamic Changes in the Activities and Contents of Particular Proteasome Forms in the Cerebral Cortex of C57BL/6 Mice during Aging].[C57BL/6小鼠衰老过程中大脑皮层特定蛋白酶体形式的活性和含量的动态变化]
Mol Biol (Mosk). 2023 Sep-Oct;57(5):886-894.
3
Proteasomes in Patient Rectal Cancer and Different Intestine Locations: Where Does Proteasome Pool Change?患者直肠癌及不同肠道部位的蛋白酶体:蛋白酶体库在何处发生变化?
Cancers (Basel). 2021 Mar 5;13(5):1108. doi: 10.3390/cancers13051108.
4
[Proteasomes on thyroid tissue allotransplantation under induction of donor specific tolerance in rats].[蛋白酶体对大鼠供体特异性耐受诱导下甲状腺组织同种异体移植的作用]
Bioorg Khim. 2014 Jan-Feb;40(1):42-54. doi: 10.1134/s1068162014010105.
5
[Immune proteasomes in the development of rat immune system].[大鼠免疫系统发育中的免疫蛋白酶体]
Bioorg Khim. 2013 Jul-Aug;39(4):400-10. doi: 10.1134/s1068162013040092.
6
The proteasome system in infection: impact of β5 and LMP7 on composition, maturation and quantity of active proteasome complexes.蛋白酶体系统在感染中的作用:β5 和 LMP7 对活性蛋白酶体复合物的组成、成熟和数量的影响。
PLoS One. 2012;7(6):e39827. doi: 10.1371/journal.pone.0039827. Epub 2012 Jun 29.
7
Proteasome functioning in breast cancer: connection with clinical-pathological factors.蛋白酶体在乳腺癌中的作用:与临床病理因素的关联
PLoS One. 2014 Oct 17;9(10):e109933. doi: 10.1371/journal.pone.0109933. eCollection 2014.
8
Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i).针对20S蛋白酶体的自身免疫反应包括免疫亚基LMP2(β1i)、MECL1(β2i)和LMP7(β5i)。
Rheumatology (Oxford). 2008 May;47(5):622-6. doi: 10.1093/rheumatology/ken042. Epub 2008 Mar 27.
9
[Features of immune proteasome expression in the development of rat central nervous system].[大鼠中枢神经系统发育过程中免疫蛋白酶体表达的特征]
Bioorg Khim. 2014 Nov-Dec;40(6):703-11. doi: 10.1134/s1068162014060119.
10
Novel propeptide function in 20 S proteasome assembly influences beta subunit composition.新型前肽在20S蛋白酶体组装中的功能影响β亚基组成。
J Biol Chem. 2000 Aug 4;275(31):24156-62. doi: 10.1074/jbc.M001742200.

引用本文的文献

1
26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy.26S 蛋白酶体非-ATP 酶调节亚基 1(PSMD1)和 3(PSMD3)作为癌症预后和治疗的潜在靶点。
Cells. 2021 Sep 11;10(9):2390. doi: 10.3390/cells10092390.
2
Proteasomes in Patient Rectal Cancer and Different Intestine Locations: Where Does Proteasome Pool Change?患者直肠癌及不同肠道部位的蛋白酶体:蛋白酶体库在何处发生变化?
Cancers (Basel). 2021 Mar 5;13(5):1108. doi: 10.3390/cancers13051108.
3
Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial.

本文引用的文献

1
The proteasome: overview of structure and functions.蛋白酶体:结构与功能概述
Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(1):12-36. doi: 10.2183/pjab.85.12.
2
Ubiquitin-independent degradation of hepatitis C virus F protein.丙型肝炎病毒F蛋白的非泛素依赖性降解
J Virol. 2009 Jan;83(2):612-21. doi: 10.1128/JVI.00832-08. Epub 2008 Oct 29.
3
Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma.硼替佐米(万珂商品名)在多发性骨髓瘤治疗中的应用。
硼替佐米与亚硫酸氢钠甲萘醌对肿瘤细胞蛋白酶体的联合作用:一项临床前试验中硼替佐米毒性的显著降低
Cancers (Basel). 2018 Sep 25;10(10):351. doi: 10.3390/cancers10100351.
4
Proteasome functioning in breast cancer: connection with clinical-pathological factors.蛋白酶体在乳腺癌中的作用:与临床病理因素的关联
PLoS One. 2014 Oct 17;9(10):e109933. doi: 10.1371/journal.pone.0109933. eCollection 2014.
Ther Clin Risk Manag. 2006 Sep;2(3):271-9. doi: 10.2147/tcrm.2006.2.3.271.
4
Neuronal nitric oxide synthase contributes to the regulation of hematopoiesis.神经元型一氧化氮合酶有助于造血作用的调节。
Mol Med. 2008 Mar-Apr;14(3-4):141-9. doi: 10.2119/2007-00011.Krasnov.
5
Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition.蛋白酶体系统对蛋白酶体抑制的适应性修饰与灵活性
Biochim Biophys Acta. 2007 Sep;1773(9):1389-97. doi: 10.1016/j.bbamcr.2007.05.007. Epub 2007 May 25.
6
WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?世界卫生组织(WHO)分级与人星形细胞瘤中MHC I类抗原加工机制成分下调的相关性:这是否反映了一种潜在的免疫逃逸机制?
Acta Neuropathol. 2007 Aug;114(2):111-9. doi: 10.1007/s00401-007-0231-8. Epub 2007 May 31.
7
20S proteasome-dependent generation of an IEpp89 murine cytomegalovirus-derived H-2L(d) epitope from a recombinant protein.由重组蛋白通过20S蛋白酶体依赖性方式产生源自鼠巨细胞病毒的IEpp89 H-2L(d)表位。
Biochem Biophys Res Commun. 2007 Apr 6;355(2):549-54. doi: 10.1016/j.bbrc.2007.02.006. Epub 2007 Feb 8.
8
Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics.通过RFDD-PCR和蛋白质组学方法观察到乳腺癌组织中泛素特异性肽酶(USPs)和蛋白酶体亚基(PSs)的基因和蛋白质过表达。
Breast Cancer Res Treat. 2007 Jul;104(1):21-30. doi: 10.1007/s10549-006-9393-7. Epub 2006 Sep 27.
9
[Immune proteasomes and immunity].[免疫蛋白酶体与免疫]
Ontogenez. 2006 May-Jun;37(3):171-8.
10
T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens.缺乏免疫蛋白酶体亚基MECL-1和LMP7的T细胞对多克隆有丝分裂原产生过度增殖反应。
J Immunol. 2006 Apr 1;176(7):4075-82. doi: 10.4049/jimmunol.176.7.4075.